dc.contributor.author | Sonnenblick, A | |
dc.contributor.author | Bailey, A | |
dc.contributor.author | Uziely, B | |
dc.contributor.author | Untch, M | |
dc.contributor.author | Smith, I | |
dc.contributor.author | Gianni, L | |
dc.contributor.author | Baselga, J | |
dc.contributor.author | Jackisch, C | |
dc.contributor.author | Cameron, D | |
dc.contributor.author | Bell, R | |
dc.contributor.author | Zardavas, D | |
dc.contributor.author | Al-Sakaff, N | |
dc.contributor.author | Gelber, RD | |
dc.contributor.author | Dowsett, M | |
dc.contributor.author | Leyland-Jones, B | |
dc.contributor.author | Piccart-Gebhart, MJ | |
dc.contributor.author | DE Azambuja, E | |
dc.date.accessioned | 2019-07-04T12:47:04Z | |
dc.date.issued | 2019-02 | |
dc.identifier.citation | Anticancer research, 2019, 39 (2), pp. 797 - 802 | |
dc.identifier.issn | 0250-7005 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3281 | |
dc.identifier.eissn | 1791-7530 | |
dc.identifier.doi | 10.21873/anticanres.13177 | |
dc.description.abstract | BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patients with HER2-positive early breast cancer (EBC) who derive differential benefit from primary adjuvant trastuzumab-based therapy. PATIENTS AND METHODS:HERA is an international randomized trial of 5,102 women with HER2-positive EBC, who were enrolled to either receive adjuvant trastuzumab or not. In this exploratory analysis, the interaction between autoimmune history and the magnitude of trastuzumab benefit was evaluated. RESULTS:A total of 5,099 patients were included in the current analysis. Among them, 325 patients (6.4%) had autoimmune disease history, 295 of whom had active disease. Patients were randomly assigned to trastuzumab or no-trastuzumab groups. Similar reductions in the risk of events in patients with and without autoimmune history were observed (interaction p=0.95 for disease-free survival, and p=0.62 for overall survival). CONCLUSION:No evidence of a differential benefit from trastuzumab in patients with a medical history of autoimmune disease was found. | |
dc.format | Print | |
dc.format.extent | 797 - 802 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Autoimmune Diseases | |
dc.subject | Disease-Free Survival | |
dc.subject | Treatment Outcome | |
dc.subject | Chemotherapy, Adjuvant | |
dc.subject | Proportional Hazards Models | |
dc.subject | Risk | |
dc.subject | International Cooperation | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Trastuzumab | |
dc.subject | Antineoplastic Agents, Immunological | |
dc.title | Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-01-10 | |
rioxxterms.versionofrecord | 10.21873/anticanres.13177 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-02 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Anticancer research | |
pubs.issue | 2 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 39 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Medicine (RMH Smith Cunningham) | en_US |
icr.researchteam | Endocrinology | en_US |
dc.contributor.icrauthor | Smith, Ian | |
dc.contributor.icrauthor | Dowsett, Mitch | |